COMMUNIQUÉS West-GlobeNewswire

PolarityBio Announces FDA Acceptance for Filing of SkinTE® BLA with Priority Review in Diabetic Foot Ulcers
15/09/2026
● PDUFA Target Action Date Set for March 16, 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolarityBio ® , a late-stage biotechnology company addressing unmet needs in wound healing through innovation in [...]
Axiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFab
15/09/2026
Strategic CDMO collaboration strengthens Axiom’s development infrastructure as the company prepares to advance its therapeutic pipeline. SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage [...]
Ontario Healthcare Stakeholders Unite on Shared Action Plan to Reduce Tobacco and Nicotine Dependence
15/09/2026
Vanguard healthcare, policy, and community stakeholders consolidate as newly formed Ontario Nicotine Action Table (ONAT) to build long-term plan for coordinated action TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- A broad [...]
Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that [...]
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
15/09/2026
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a [...]
Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases
15/09/2026
Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026 NESS ZIONA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE [...]
Eleva separates Bryotechnology platform and clinical-stage Factor H biotherapeutic into independent companies
15/09/2026
Eleva Biologics will seek strategic partnerships for development and manufacturing of first-in-class and previously inaccessible biologics discovered with the Bryotechnology platform One04 Therapeutics will focus on [...]
One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD
15/09/2026
CPV-104 interim Phase 1 results support favorable safety and tolerability, with encouraging early efficacy trends in patients with C3 glomerulopathy Detailed interim Phase 1 data to be released in a virtual event after [...]
C4X Discovery establishes in vivo proof of concept for its PAD4 inhibitor programme
15/09/2026
A potent and selective PAD4 inhibitor demonstrates efficacy comparable to an anti-TNFα biologic in a mouse model of arthritis 15 September 2026 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company [...]
ENA Respiratory Begins Part B Dosing in INNA-051 Phase IIa Community Study Designed to Protect Against Symptomatic Viral Respiratory Infections
15/09/2026
MELBOURNE, Australia, Sept. 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral [...]
Transactions in connection with share buy-back program
15/09/2026
Company announcement no. 35 - 26 15 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Children’s National ranked among top children’s hospitals nationwide and highest in the DMV by U.S. News & World Report
15/09/2026
Ranked in all 11 specialties, with top 10 honors in neurology and neurosurgery, cancer, orthopedics, gastroenterology and GI surgery, neonatology, and diabetes and endocrinology Washington, DC, Sept. 15, 2026 (GLOBE [...]
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
15/09/2026
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “ Company ” [...]
DLH Appoints Brooke Pierce President of Health Business Group
14/09/2026
ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today [...]
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
14/09/2026
BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Curium™ announced today [...]
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
15/09/2026
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis - Ascendis to initiate multiple programs in metabolic and [...]
Ascendis Announces Planned $400 Million Share Repurchase Program
15/09/2026
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s [...]
From Former Patient to Clinical Leader: Oxford Treatment Center Promotes Kate Bell to Outpatient Clinical Manager
15/09/2026
OXFORD, Miss., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Oxford Treatment Center is pleased to announce the promotion of Kate Bell, NCC, LPC , to Outpatient Clinical Manager. Bell first came to Oxford Treatment Center as a [...]
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
15/09/2026
SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health [...]

Pages